ARDEGO THERAPEUTICS
Getting a Jump on Cancer.
Ardego Therapeutics is advancing breakthrough precision-targeting technology designed to help therapies reach and engage cancer cells previously considered difficult, impractical, or impossible to access.
Ardego's proprietary platform is expanding what can be targeted in cancer treatment by creating new opportunities for more effective therapies with the potential for lower toxicity, fewer debilitating side effects, and better patient outcomes.
Supported by encouraging early pre-clinical results, Ardego is advancing a new frontier in precision-targeted therapeutics.
patent protected TECHNOLOGY
A New Frontier in Precision Cancer Cell Targeting
Many targeted therapies are nothing more than carefully dosed toxin medicines with higher propensity to engage cancer cells give their higher cell surface markers of interest. Ardego is designing a truly unique system for cancer treatment were cancer cells are selectively targeted at multiple checkpoints and ultimately arrested as a result of a specific oncogene presence.
Ardego's proprietary platform combines antibody targeting, tumor-selective activation, and therapeutic oligonucleotides into a novel delivery system designed to help therapies engage cancer cells with a level of precision and potency not previously achievable.
By expanding what can be targeted, we are expanding what may be possible in cancer treatment.
Precision Changes What's Possible.
Join us as we advance the next generation of precision-targeted therapeutics and expand what's possible in the fight against cancer.
Greater Precision
Designed to selectively engage targeted cancer cells while minimizing unintended impact on healthy tissue.
Greater Potency
Efficient delivery of therapeutic oligonucleotides to the right place enables more effective target engagement.
Expanded Therapeutic Opportunity
Opening new possibilities for therapies targeting cancer cells previously considered difficult or impossible to reach.
Potential Lower Toxicity
Fewer debilitating side effects
The potential for better tolerated therapies, improved quality of life, and better patient outcomes.
More precise delivery reduces exposure of healthy tissue to the therapeutic payload.
Greater Precision
Designed to selectively engage targeted cancer cells while minimizing unintended impact on healthy tissue.
Greater Potency
Efficient delivery of therapeutic oligonucleotides to the right place enables more effective target engagement.
Expanded Therapeutic Opportunity
Opening new possibilities for therapies targeting cancer cells previously considered difficult or impossible to reach.
Potential Lower Toxicity
More precise delivery reduces exposure of healthy tissue to the therapeutic payload.
Fewer Debilitating Side Effects
The potential for better tolerated therapies, improved quality of life, and better patient outcomes.
MARKET OPPORTUNITY
A Platform Designed for the Future
Ardego is developing more than a single therapeutic.
They are advancing a precision-targeting platform with the potential to support multiple therapeutic strategies and future oncology applications.
Supported by encouraging preclinical results, Ardego's technology represents an exciting opportunity at the intersection of targeted therapeutics, oligonucleotide science, and precision delivery.
